VIAL
Home/Compounds/Semax
RecoveryGrey AreaClinical Trials

Semax

About

About Semax

Semax is a synthetic heptapeptide derived from ACTH and developed in Russia, where it is approved and widely prescribed for cognitive decline, stroke recovery, and ADHD. It upregulates BDNF and NGF, making it one of the few compounds with strong neurotrophic evidence. Western use is primarily through compounding pharmacies and research chemical suppliers. It is intranasal and demonstrates rapid CNS penetration.

Science

Mechanism of Action

Stimulates production of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus and cortex; also modulates dopamine and serotonin systems to enhance working memory and attention.

Dosing

Typical Protocol

200–900 mcg intranasal spray once or twice daily for 14–28 day cycles; available as 0.1% or 1% solution.

⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.

Regulatory

Legal Status in 2026

Grey Area

This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.

Evidence

Evidence Tier

Clinical Trials

Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.

Find a Verified Provider

See which Vial-verified providers offer Semax — with trust scores, legal credentials, and pricing transparency.

Browse all verified providers →